FindTrial
Sign In

Examination of the treatment prediction factor of Ombitasvir/Paritaprevir/Ritonavir in chronic hepatitis C of Genotype1b.

Examination of the treatment prediction factor of Ombitasvir/Paritaprevir/Ritonavir in chronic hepatitis C of Genotype1b. - Examination of the treatment prediction factor of Ombitasvir/Paritaprevir/Ritonavir in chronic hepatitis C of Genotype1b.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027859
Enrollment
500
Registered
2017-06-22
Start date
2015-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Treat with Ombitasvir/Paritaprevir/Ritonavir combination therapy.

Sponsors

Nippon Medical School Hospital Nippon Medical School Musashi Kosugi Hospital The Jikei University Hospital Otakanomori Hospital Hakujikai Healthcare foundation Tokyo Metropolitan Bokutoh Hospital Tokyo Medical University Ibaraki Medical Center Shinmatsudo Central General Hospital Japanese Red Cross Narita Hospital
Collaborator
Nippon Medical School Chiba Hokusoh Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients were treated with Ombitasvir/Paritaprevir/Ritonavir combination therapy

Exclusion criteria

Exclusion criteria: 1.History of allergy to Ombitasvir/Paritaprevir/Ritonavir 2.Decompensated liver cirrhosis 3.pregnant woman or lactating mother 4.Hepatocellular carcinoma, or other malignant tumor. 5.severe depression 6.Judged by investigator not to be appropriate for inclusion in this study 7.Receiving contraindicated drugs for Ombitasvir/Paritaprevir/Ritonavir combined therapy

Design outcomes

Primary

MeasureTime frame
Sustained virological response rate—

Secondary

MeasureTime frame
1. Change in serum HCV RNA during treatment and follow-up duration 2. Change in hematological and biochemical test during treatment and follow-up duration 3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration.—

Countries

Japan

Contacts

Public ContactMasanori Atsukawa

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

atsukawa-nms@umin.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026